Gold bars to be exempt from tariffs, White House clarifies
SUNNYVALE, Calif. - Medical technology company Ceribell, Inc. (NASDAQ:CBLL), currently valued at $684 million, announced Monday it has filed complaints against Natus Medical Incorporated, alleging patent infringement and unfair competition.
The company filed a complaint with the U.S. International Trade Commission (USITC) requesting an investigation and an exclusion order to prevent importation of allegedly infringing Natus products into the United States. Ceribell also filed a separate complaint in the U.S. District Court in Delaware.
According to the press release statement, Ceribell claims Natus is infringing on six of its patents related to EEG headband and electrode design features.
"From clinical research to continuous product advancements, Ceribell has made significant investments in point-of-care EEG technology," said Jane Chao, Ph.D., co-founder and CEO of Ceribell. "We will vigorously protect our intellectual property against infringement."
Ceribell develops electroencephalography (EEG) technology for diagnosing and managing neurological conditions in acute care settings. The company’s FDA-cleared Ceribell System is designed for rapid deployment in intensive care units and emergency rooms.
The litigation comes as Ceribell seeks to protect what it describes as its innovations in the healthcare technology space. With analyst price targets ranging from $26 to $36 per share, InvestingPro subscribers can access 7 additional key insights about Ceribell’s financial health and growth prospects through the comprehensive Pro Research Report, which provides detailed analysis of the company’s market position and future potential. According to InvestingPro data, Ceribell demonstrates impressive gross profit margins of 87% and strong revenue growth of 45% in the last twelve months, though analysts expect net income to decrease this year.
In other recent news, Ceribell Inc. reported a notable 42% increase in total revenue for the first quarter of 2025, reaching $20.5 million. Despite a net loss of $12.8 million, the company raised its full-year revenue guidance to between $83 million and $87 million, reflecting management’s confidence in sustained growth. Additionally, Ceribell received FDA clearance for a new pediatric seizure detection algorithm, expanding its addressable market. During the company’s 2025 Annual Meeting of Stockholders, Juliet Tammenoms Bakker and Lucian Iancovici, M.D. were elected as directors, and PricewaterhouseCoopers LLP was ratified as the independent auditor for the fiscal year. Meanwhile, TD Cowen maintained a Buy rating and a $36.00 price target for Ceribell, citing potential benefits from easing US-China trade tensions. The firm highlighted Ceribell’s robust financial health and high gross margins despite tariff challenges. Investors are closely watching trade discussions, as any positive developments could improve Ceribell’s cost structure and profitability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.